Supernus Price to Sales Ratio vs Interest Coverage Analysis
SUPN Stock | USD 29.00 0.43 1.46% |
Supernus Pharmaceuticals financial indicator trend analysis is much more than just breaking down Supernus Pharmaceuticals prevalent accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether Supernus Pharmaceuticals is a good investment. Please check the relationship between Supernus Pharmaceuticals Price To Sales Ratio and its Interest Coverage accounts. Check out World Market Map to better understand how to build diversified portfolios, which includes a position in Supernus Pharmaceuticals. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in american community survey. To learn how to invest in Supernus Stock, please use our How to Invest in Supernus Pharmaceuticals guide.
Price To Sales Ratio vs Interest Coverage
Price to Sales Ratio vs Interest Coverage Correlation Analysis
The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of Supernus Pharmaceuticals Price to Sales Ratio account and Interest Coverage. At this time, the significance of the direction appears to have strong contrarian relationship.
The correlation between Supernus Pharmaceuticals' Price to Sales Ratio and Interest Coverage is -0.52. Overlapping area represents the amount of variation of Price to Sales Ratio that can explain the historical movement of Interest Coverage in the same time period over historical financial statements of Supernus Pharmaceuticals, assuming nothing else is changed. The correlation between historical values of Supernus Pharmaceuticals' Price to Sales Ratio and Interest Coverage is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Price to Sales Ratio of Supernus Pharmaceuticals are associated (or correlated) with its Interest Coverage. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Interest Coverage has no effect on the direction of Price to Sales Ratio i.e., Supernus Pharmaceuticals' Price to Sales Ratio and Interest Coverage go up and down completely randomly.
Correlation Coefficient | -0.52 |
Relationship Direction | Negative |
Relationship Strength | Very Weak |
Price To Sales Ratio
Price to Sales Ratio is figured by comparing Supernus Pharmaceuticals stock price to its revenues. An advantage to using Price to Sales ratio is that it is based on Supernus Pharmaceuticals sales, a figure that is much harder to manipulate than other Supernus Pharmaceuticals multiples. Because sales tend to be more stable P/S ratio can be a good tool for screening cyclical companies fluctuating earnings patterns. A valuation ratio that compares a company’s stock price to its revenues, calculated by dividing the company’s market cap by its total sales or revenue over a 12-month period.Interest Coverage
Most indicators from Supernus Pharmaceuticals' fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into Supernus Pharmaceuticals current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out World Market Map to better understand how to build diversified portfolios, which includes a position in Supernus Pharmaceuticals. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in american community survey. To learn how to invest in Supernus Stock, please use our How to Invest in Supernus Pharmaceuticals guide.At this time, Supernus Pharmaceuticals' Tax Provision is very stable compared to the past year. As of the 18th of April 2024, Issuance Of Capital Stock is likely to grow to about 8.4 M, while Selling General Administrative is likely to drop about 85.1 M.
2021 | 2022 | 2023 | 2024 (projected) | Interest Expense | 23.4M | 7.1M | 2.4M | 2.3M | Depreciation And Amortization | 34.0M | 82.6M | 84.9M | 89.1M |
Supernus Pharmaceuticals fundamental ratios Correlations
Click cells to compare fundamentals
Supernus Pharmaceuticals Account Relationship Matchups
High Positive Relationship
High Negative Relationship
Supernus Pharmaceuticals fundamental ratios Accounts
2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
Common Stock Shares Outstanding | 53.8M | 53.7M | 54.4M | 61.7M | 55.5M | 42.6M | |
Total Assets | 1.2B | 1.5B | 1.7B | 1.7B | 1.4B | 1.5B | |
Short Long Term Debt Total | 375.6M | 390.3M | 420.6M | 438.0M | 41.5M | 39.5M | |
Other Current Liab | 3.2M | 40.0M | 65.0M | 139.8M | 279.9M | 293.9M | |
Total Current Liabilities | 160.6M | 245.1M | 315.4M | 688.0M | 290.2M | 154.7M | |
Total Stockholder Equity | 595.4M | 744.9M | 815.9M | 886.2M | 921.5M | 967.6M | |
Property Plant And Equipment Net | 38.3M | 37.8M | 17.0M | 15.2M | 42.5M | 44.7M | |
Net Debt | 194.2M | 101.7M | 217.1M | 344.8M | (33.5M) | (31.9M) | |
Retained Earnings | 199.5M | 326.5M | 379.9M | 481.2M | 482.6M | 506.7M | |
Accounts Payable | 10.1M | 78.9M | 117.7M | 96.3M | 2.0M | 1.9M | |
Cash | 181.4M | 288.6M | 203.4M | 93.1M | 75.1M | 116.1M | |
Non Current Assets Total | 687.6M | 873.7M | 1.1B | 968.4M | 915.9M | 961.7M | |
Non Currrent Assets Other | 615K | 8.0M | (36.1M) | (10.0M) | 8.5M | 8.9M | |
Cash And Short Term Investments | 347.1M | 422.5M | 339.7M | 461.3M | 254.9M | 201.2M | |
Net Receivables | 87.3M | 140.9M | 148.9M | 165.5M | 144.2M | 151.4M | |
Common Stock Total Equity | 51K | 52K | 53K | 54K | 62.1K | 40.8K | |
Short Term Investments | 165.7M | 133.9M | 136.2M | 368.2M | 179.8M | 98.1M | |
Liabilities And Stockholders Equity | 1.2B | 1.5B | 1.7B | 1.7B | 1.4B | 1.5B | |
Non Current Liabilities Total | 404.3M | 514.1M | 557.9M | 128.3M | 197.3M | 179.2M | |
Inventory | 26.6M | 48.3M | 86.0M | 91.5M | 77.4M | 81.3M | |
Other Current Assets | 11.6M | 18.7M | 27.0M | 15.8M | 16.7M | 8.5M | |
Other Stockholder Equity | 388.4M | 409.3M | 434.3M | 408.1M | 439.5M | 279.8M | |
Total Liab | 564.9M | 759.2M | 873.3M | 816.3M | 487.5M | 333.9M | |
Property Plant And Equipment Gross | 38.3M | 37.8M | 33.4M | 28.2M | 28.9M | 30.4M | |
Total Current Assets | 472.6M | 630.4M | 601.6M | 734.2M | 493.1M | 305.3M | |
Accumulated Other Comprehensive Income | 7.4M | 9.0M | 1.5M | (3.2M) | (593K) | (563.4K) | |
Intangible Assets | 24.8M | 442.3M | 784.7M | 702.5M | 599.9M | 629.9M | |
Common Stock | 51K | 52K | 53K | 54K | 55K | 42.0K | |
Other Liab | 28.7M | 123.8M | 137.4M | 92.3M | 106.2M | 111.5M | |
Other Assets | 32.7M | 259.7M | 13.9M | 10.9M | 12.5M | 11.9M | |
Long Term Debt | 329.5M | 345.2M | 361.8M | 379.3M | 436.1M | 457.9M | |
Property Plant Equipment | 17.1M | 37.8M | 52.3M | 44.1M | 50.7M | 53.2M | |
Net Tangible Assets | 570.6M | 302.6M | (86.4M) | 66.7M | 76.7M | 72.9M | |
Good Will | 24.8M | 77.9M | 117.5M | 117.0M | 134.6M | 141.3M | |
Retained Earnings Total Equity | 199.5M | 326.5M | 379.9M | 481.2M | 553.4M | 581.1M | |
Capital Surpluse | 388.4M | 409.3M | 434.3M | 408.1M | 469.3M | 352.1M |
Currently Active Assets on Macroaxis
When determining whether Supernus Pharmaceuticals offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Supernus Pharmaceuticals' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Supernus Pharmaceuticals Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Supernus Pharmaceuticals Stock:Check out World Market Map to better understand how to build diversified portfolios, which includes a position in Supernus Pharmaceuticals. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in american community survey. To learn how to invest in Supernus Stock, please use our How to Invest in Supernus Pharmaceuticals guide.You can also try the CEOs Directory module to screen CEOs from public companies around the world.
Complementary Tools for Supernus Stock analysis
When running Supernus Pharmaceuticals' price analysis, check to measure Supernus Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Supernus Pharmaceuticals is operating at the current time. Most of Supernus Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Supernus Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Supernus Pharmaceuticals' price. Additionally, you may evaluate how the addition of Supernus Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.
Portfolio Volatility Check portfolio volatility and analyze historical return density to properly model market risk | |
Premium Stories Follow Macroaxis premium stories from verified contributors across different equity types, categories and coverage scope | |
Sync Your Broker Sync your existing holdings, watchlists, positions or portfolios from thousands of online brokerage services, banks, investment account aggregators and robo-advisors. | |
Global Markets Map Get a quick overview of global market snapshot using zoomable world map. Drill down to check world indexes | |
Idea Optimizer Use advanced portfolio builder with pre-computed micro ideas to build optimal portfolio | |
Equity Search Search for actively traded equities including funds and ETFs from over 30 global markets |
Is Supernus Pharmaceuticals' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Supernus Pharmaceuticals. If investors know Supernus will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Supernus Pharmaceuticals listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth (0.96) | Earnings Share 0.02 | Revenue Per Share 11.14 | Quarterly Revenue Growth (0.02) | Return On Assets 0.0056 |
The market value of Supernus Pharmaceuticals is measured differently than its book value, which is the value of Supernus that is recorded on the company's balance sheet. Investors also form their own opinion of Supernus Pharmaceuticals' value that differs from its market value or its book value, called intrinsic value, which is Supernus Pharmaceuticals' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Supernus Pharmaceuticals' market value can be influenced by many factors that don't directly affect Supernus Pharmaceuticals' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Supernus Pharmaceuticals' value and its price as these two are different measures arrived at by different means. Investors typically determine if Supernus Pharmaceuticals is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Supernus Pharmaceuticals' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.